Your browser doesn't support javascript.
loading
Clinical efficacy of alprostadil combined with levocarnitine in treatment of chronic renal failure combined with heart failure / 药物评价研究
Drug Evaluation Research ; (6): 683-686, 2017.
Article Dans Chinois | WPRIM | ID: wpr-619627
ABSTRACT
Objective To discuss the efficacy of alprostadil and levocarnitine in treatment of chronic renal failure combined with heart failure.Methods Totally 80 patients with chronic renal failure complicated with heart failure were selected,and randomly divided into two groups.The control group (39 cases) was given alprostadil.The observation group (41 cases) was given alprostadil and levocarnitine.The efficacy of alprostadil and levocamitine in treatment of chronic renal failure combined with heart failure was evaluated by cardiac fimction indexes,renal function indexes,SF-36 scale score,and adverse reaction during the treatment.Results Before treatment,there was no statistical significance on CO,CI,MVO,and EF between two groups.After treatment,the CO,CI,and MVO were decreased and lower in the observation group (P < 0.05).The EF was increased in the observation group and higher than that of the control group (P < 0.05).The EF had no changes in the control group.Before treatment,there was no statistical significance on CysC,BUN,and SCr between two groups before treatment,without statistical significance.After treatment,CysC,BUN,and SCr were decreased in two groups and lower in the observation group (P < 0.05).Before treatment,there was no statistical significance on SF-36 scores between two groups.After treatment,the physiological function,physical function,and general health were higher than those of the control group (P < 0.05).There was no statistical significance on the rest of the scores.During treatment,there was no statistical significance on adverse reaction between two groups.Conclusion Alprostadil and levocarnitine had a good curative effect on chronic renal failure combined with heart failure.It could improve the heart function by reducing cardiac load,improve the renal function by increasing glomerular filtration rate and improve the quality of life with good safety.It is worthy of clinical application.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Drug Evaluation Research Année: 2017 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Drug Evaluation Research Année: 2017 Type: Article